Antiretroviral therapeutic possibilities for human immunodeficiency virus/acquired immunodeficiency syndrome.
In human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) illness, the reverse transcriptase and protease (PRT) enzymes of HIV are currently the targets of antiretroviral (ARV) therapy. Nucleoside analogues were the first group of ARV drugs that exerted antiviral activity in patients. More recently, PRT inhibitors have provided new approaches in the treatment of HIV infection and AIDS. Impressive clinical results have been obtained with combination therapies of three ARV drugs, including one PRT inhibitor. It is worth mentioning also that apart from these two main drug groups, there are many new compounds under development, including a vaccine(s) against HIV.
Balint
G A
GA
Laboratory of Clinical Pharmacology, Department of Psychiatry, New Clinics, University of Szeged, Medical Faculty, G.P.O. Box 427, H-6701 Szeged, Hungary. balint@nepsy.szote.u-szeged.hu
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral; D005544:Forecasting; D017320:HIV Protease Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors